PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 93 filers reported holding PMV PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $882,202 | +44.2% | 143,681 | +47.0% | 0.00% | – |
| Q2 2023 | $611,721 | +43.1% | 97,719 | +9.0% | 0.00% | – |
| Q1 2023 | $427,601 | -82.7% | 89,644 | -68.5% | 0.00% | -100.0% |
| Q4 2022 | $2,474,176 | +73.5% | 284,388 | +137.3% | 0.00% | 0.0% |
| Q3 2022 | $1,426,000 | -71.4% | 119,845 | -65.8% | 0.00% | -50.0% |
| Q2 2022 | $4,992,000 | +26.9% | 350,310 | +85.3% | 0.00% | +100.0% |
| Q1 2022 | $3,935,000 | +32.2% | 189,011 | +46.6% | 0.00% | 0.0% |
| Q4 2021 | $2,977,000 | +4.0% | 128,907 | +34.2% | 0.00% | 0.0% |
| Q3 2021 | $2,862,000 | +7635.1% | 96,038 | +8776.0% | 0.00% | – |
| Q2 2021 | $37,000 | -91.3% | 1,082 | -91.6% | 0.00% | – |
| Q1 2021 | $426,000 | +174.8% | 12,939 | +412.2% | 0.00% | – |
| Q4 2020 | $155,000 | +675.0% | 2,526 | +342.4% | 0.00% | – |
| Q3 2020 | $20,000 | – | 571 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |